Refined USP25/28 inhibitors with improved selectivity towards c-Myc driven squamous lung cancer cells
Pinto-Fernandez, A.; Heride, C.; Turnbull, A. P.; Krajewski, W. W.; Bell, C.; Pedroso, D.; Smith, V.; Mullee, L.; Varca, A.; Charlton, T.; Jones, D. T.; McAllister, T.; Fischer, R.; Guerrero, E. N.; Ebner, D.; Kawamura, A.; Kim, S.; Guerin, D.; Hammonds, T. R.; Kearns, J.; Jones, N.; Buhrlage, S. J.; Urbe, S.; Komander, D.; Clague, M.; Kessler, B. M.
Show abstract
The ubiquitin specific protease 28 (USP28) is implicated in tumorigenesis by controlling the turnover of the oncogene c-MYC and the ubiquitin ligase FBW7. Here, we describe small molecule inhibitors of USP25 and USP28, leading to cancer cell cycle arrest and death. However, genetic deletion of USP25/28 does not replicate this effect. An integrated -omics approach revealed off-target effects for thienopyridine carboxamide compounds upon the translation apparatus. Chemoproteomics and CRISPR-GOF analyses suggested binding of the compound to a region near the ribosome complex polypeptide exit tunnel. Structural analysis of a USP28-inhibitor complex enabled the design of modified USP25/28 inhibitor molecules which minimized translation-related off-target effects. In distinction to earlier compounds, the optimized inhibitors were non-toxic to breast cancer cells yet retained potent anti-proliferative activity in squamous lung carcinoma cells, where USP28 is associated with disease progression. Together, our results demonstrate that refined USP25/28 inhibitors can selectively suppress tumor growth by targeting the TP63-FBW7-c-MYC signaling axis, offering a more precise therapeutic strategy for treating squamous lung cancers whilst minimizing undesired cytotoxicity.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.